TriSalus Life Sciences (NASDAQ:TLSI) Stock Rating Lowered by Wall Street Zen

TriSalus Life Sciences (NASDAQ:TLSI) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.

TLSI has been the subject of a number of other research reports. Zacks Research upgraded TriSalus Life Sciences to a “hold” rating in a report on Thursday, September 10th. Guggenheim set a $12.00 target price on shares of TriSalus Life Sciences in a research note on Wednesday, September 23rd. Stifel Nicolaus set a $12.00 price objective on TriSalus Life Sciences in a research report on Wednesday, September 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Wednesday. Finally, HC Wainwright raised their target price on TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, September 23rd. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $10.20.

TriSalus Life Sciences Price Performance

NASDAQ:TLSI opened at $3.25 on Friday. The company has a 50-day moving average of $4.28 and a 200 day moving average of $4.36. The company has a quick ratio of 4.97, a current ratio of 5.35 and a debt-to-equity ratio of 5.05. TriSalus Life Sciences has a 1-year low of $2.20 and a 1-year high of $7.95.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.16). The business had revenue of $11.41 million for the quarter, compared to analysts’ expectations of $10.27 million. Research analysts anticipate that TriSalus Life Sciences will post -0.53 EPS for the current fiscal year.

Institutional Investors Weigh In On TriSalus Life Sciences

Several hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. acquired a new stake in shares of TriSalus Life Sciences during the third quarter valued at approximately $68,000. Provenance Wealth Advisors LLC acquired a new stake in TriSalus Life Sciences in the 3rd quarter valued at $94,000. CWA Asset Management Group LLC bought a new stake in shares of TriSalus Life Sciences during the 3rd quarter valued at $310,000. State Street Corp increased its stake in TriSalus Life Sciences by 86.3% in the 2nd quarter. State Street Corp now owns 610,963 shares of the company’s stock worth $2,780,000 after purchasing an additional 282,943 shares during the period. Finally, First Light Asset Management LLC lifted its position in TriSalus Life Sciences by 29.3% in the 2nd quarter. First Light Asset Management LLC now owns 6,552,491 shares of the company’s stock valued at $29,814,000 after acquiring an additional 1,485,664 shares in the last quarter. 2.58% of the stock is owned by institutional investors and hedge funds.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences is an oncology-focused healthcare company developing technologies and therapies for patients with liver and pancreatic tumors. The company combines medical devices, drug-delivery systems and immunotherapy programs to address tumors that may be difficult to treat with conventional approaches.

Its core technology is Pressure-Enabled Drug Delivery (PEDD), a platform designed to improve the delivery of therapeutic agents directly to tumors through the arterial blood supply.